Title

A cohort study of the effects of serum OPG and OPG gene polymorphisms on cardiovascular mortality in elderly women

Document Type

Journal Article

Publisher

Wiley

Faculty

Computing, Health and Science

School

Exercise, Biomedical and Health Science

Comments

This article was originally published as: Ueland, T., Dick, I. M., Wilson, S. G., Islam, A. F. M., Mullin, B., Devine, A., ... & Prince, R. L. (2006, September). A cohort study of the effects of serum OPG and OPG gene polymorphisms on the development of coronary artery disease in elderly women. In Clinical Endocrinology. 71(6), 828-833. doi: 10.1111/j.1365-2265.2009.03605.x

Original article available here

Abstract

Objective: To investigate the role of serum osteoprotegerin (OPG) and OPG gene polymorphisms in relation to cardiovascular (CV) and all-cause mortality in elderly women. Background: The OPG/RANK/RANKL plays a vital role in bone cell biology. It has also been detected in myocardial tissue and atherosclerotic plaques. In some population studies, OPG and OPG gene polymorphisms have been associated with CV disease risk. Design, measurements and results: In an 8·5-year cohort population study of 1333 postmenopausal women mean age 75·2 ± 2·7 years, serum OPG concentrations above the median were associated with an increased risk of all-cause [odds ratio (OR) 1·39 (1·04-1·85)], and in particular CV mortality [OR 1·83 (1·10-3·05)], before and after adjusting for age, BMI, treated hypertension, diabetes, hypercholesterolemia, previous HRT use, calcium supplementation and smoking. Genotyping the OPG gene did not provide further information on the association between OPG and CV risk or mortality events. Conclusions: Raised osteoprotegerin appears to be an independent risk factor for total and CV death and thus has potential as a useful biomarker of risk as well as a potential target for therapeutic intervention.

DOI

10.1111/j.1365-2265.2009.03605.x

 

Link to publisher version (DOI)

10.1111/j.1365-2265.2009.03605.x